Takeda has updated its full year Management Guidance for Revenue primarily due to VYVANSE and raised full year forecasts to reflect cost discipline and FX tailwind.









FY2025 Management Guidance Core Change at CER (Non-IFRS)





Item



FY2025 PREVIOUS MANAGEMENT GUIDANCE
(October 2025)



FY2025 REVISED MANAGEMENT GUIDANCE
(January 2026)





Core Revenue



Broadly flat



Low-single-digit % decline





Core Operating Profit



Low-single-digit % decline



Low-single-digit % decline





Core EPS



Low-single-digit % decline



Low-single-digit % decline












=*=*=*=*=*=
当前为第6/18页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页